Bank of America Lowers Enhabit (NYSE:EHAB) Price Target to $8.00

Enhabit (NYSE:EHAB) had its price target lowered by Bank of America from $9.00 to $8.00 in a research report released on Thursday, Benzinga reports. The firm currently has an underperform rating on the stock.

EHAB has been the subject of several other reports. Leerink Partnrs upgraded shares of Enhabit from a strong sell rating to a hold rating in a research report on Tuesday, May 14th. UBS Group upgraded Enhabit from a sell rating to a neutral rating and set a $9.50 price objective for the company in a research note on Thursday, March 7th. Jefferies Financial Group downgraded Enhabit from a buy rating to a hold rating and lowered their target price for the company from $14.00 to $8.75 in a research report on Thursday, May 9th. Oppenheimer restated a market perform rating on shares of Enhabit in a research report on Thursday, March 7th. Finally, SVB Leerink raised Enhabit from an underperform rating to a market perform rating and set a $8.50 price objective on the stock in a research report on Tuesday, May 14th. One equities research analyst has rated the stock with a sell rating and seven have given a hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of Hold and an average target price of $9.79.

Enhabit Trading Up 4.1 %

NYSE:EHAB opened at $8.92 on Thursday. The company has a 50 day simple moving average of $9.19 and a two-hundred day simple moving average of $9.88. The company has a market cap of $447.43 million, a PE ratio of -5.37, a price-to-earnings-growth ratio of 1.37 and a beta of 1.88. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of 0.75. Enhabit has a 12 month low of $7.12 and a 12 month high of $14.59.

Enhabit (NYSE:EHAB) last posted its quarterly earnings data on Wednesday, May 8th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.02. The company had revenue of $262.40 million during the quarter, compared to analysts’ expectations of $268.25 million. Enhabit had a positive return on equity of 1.43% and a negative net margin of 7.95%. Research analysts forecast that Enhabit will post 0.24 earnings per share for the current year.

Insider Activity at Enhabit

In other Enhabit news, Director Jeffrey Bolton purchased 10,000 shares of the company’s stock in a transaction on Friday, May 10th. The stock was acquired at an average cost of $8.24 per share, for a total transaction of $82,400.00. Following the purchase, the director now directly owns 42,299 shares of the company’s stock, valued at approximately $348,543.76. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders have acquired 22,000 shares of company stock valued at $183,700. 1.90% of the stock is owned by company insiders.

Institutional Trading of Enhabit

Several hedge funds have recently bought and sold shares of EHAB. JANA Partners Management LP bought a new stake in shares of Enhabit in the third quarter worth about $20,532,000. Kent Lake Capital LLC purchased a new stake in shares of Enhabit during the 1st quarter worth approximately $5,183,000. DekaBank Deutsche Girozentrale raised its holdings in shares of Enhabit by 12,146.2% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 244,924 shares of the company’s stock worth $2,543,000 after acquiring an additional 242,924 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Enhabit by 25.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 966,515 shares of the company’s stock valued at $10,003,000 after acquiring an additional 193,675 shares during the last quarter. Finally, 8 Knots Management LLC purchased a new position in shares of Enhabit in the fourth quarter valued at $1,968,000.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.